ICU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SeaStar Medical Holding Corp (ICU) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the company has shown positive developments in its clinical trials and revenue growth, the financial performance remains weak with significant losses, and there are no strong technical or trading signals to support immediate entry. The lack of recent congressional trading data, neutral insider/hedge fund activity, and absence of proprietary trading signals further reinforce a cautious approach.
The MACD is positive but contracting, indicating a weakening bullish momentum. RSI is neutral at 53.701, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. The current price is near the pivot level of 2.573, with key resistance at 2.804 and support at 2.342.
Completion of patient enrollment for the SAVE Registry to confirm the safety of QUELIMMUNE therapy for pediatric acute kidney injury. Positive clinical experience published in a peer-reviewed journal.
Significant share dilution reflected in the lowered price target by analysts. Weak financial performance with declining net income, EPS, and gross margin.
In Q3 2025, revenue increased by 169.12% YoY to $183,000, but net income dropped by 22.47% YoY to -$3,472,000. EPS declined sharply by 87.96% YoY to -1.32, and gross margin fell by 7.65% YoY to 92.35%.
Maxim lowered the price target from $10 to $6 while maintaining a Buy rating, citing share dilution despite positive clinical developments.
